ETFAD/EADV湿疹工作组2020年成人与儿童特应性皮炎诊疗立场文件
该立场文件由ETFAD/EADV湿疹工作组制定,系统阐述成人与儿童特应性皮炎的诊断标准、疾病活动度评估(如SCORAD)、基础治疗、外用抗炎药物、主动治疗、系统治疗及辅助治疗等推荐。文件强调根据临床与致病异质性、患者年龄及预防复发进行管理,并指出度普利尤单抗是安全有效但昂贵的选项,口服糖皮质激素效益风险比不利。
要点
- 诊断采用经过评价的临床标准,疾病活动与负担用SCORAD等复合评分评估。
- 基础治疗包括普遍使用保湿和屏障稳定外用制剂,并避免特异及非特异诱发因素。
- 外用糖皮质激素和钙调神经磷酸酶抑制剂(他克莫司、吡美莫司)用于可见皮损,敏感部位优先后者。
核心结论
- 特应性皮炎管理需考虑临床与致病异质性、患者年龄并注重预防复发。
- 基础治疗为普遍使用保湿和屏障稳定外用制剂并避免诱发因素。
- 度普利尤单抗是安全有效但昂贵的治疗选项,口服糖皮质激素效益风险比大多不利。
研究设计与样本
- 由ETFAD/EADV湿疹工作组制定的立场文件,覆盖成人与儿童特应性皮炎诊断与治疗。
主要发现
- 诊断基于经过评价的临床标准,疾病活动与负担最好用包含客观和主观症状的复合评分如SCORAD衡量。
- 外用他克莫司和部分中效糖皮质激素被证明可用于主动治疗,即对频繁复发皮肤区域进行长期间歇抗炎治疗。
- 度普利尤单抗是安全、有效且有许可但昂贵的治疗选项,具有潜在眼部副作用。
- 系统抗组胺药(H1R阻滞剂)对特应性皮炎相关瘙痒和湿疹皮损效果有限。
- 辅助治疗包括紫外线照射(优选窄谱UVB或UVA1),煤焦油可能对特应性手足湿疹有用。
关键数值与推荐
- 诊断使用经过评价的临床标准,疾病活动与负担用SCORAD等复合评分评估。
- 可见皮损使用外用抗炎药如糖皮质激素和钙调神经磷酸酶抑制剂(他克莫司和吡美莫司),敏感部位优先后者。
- 主动治疗定义为对频繁复发皮肤区域的长期间歇抗炎治疗,外用他克莫司和部分中效糖皮质激素被证明适用。
- 饮食建议应个体化,仅在有证实食物过敏时建议排除饮食。
- 推荐对儿童和成人使用经证实有效的「湿疹学校」教育项目和患者治疗教育。
临床怎么用
- 临床中应使用经过评价的临床标准诊断特应性皮炎,并用SCORAD等复合评分评估疾病活动与负担。
- 对所有患者普遍应用保湿和屏障稳定外用治疗,并避免特异及非特异诱发因素。
- 可见皮损使用外用糖皮质激素或钙调神经磷酸酶抑制剂,敏感部位优先选择后者。
- 对频繁复发部位可考虑外用他克莫司或部分中效糖皮质激素进行长期间歇主动治疗。
- 系统治疗需监测,口服糖皮质激素因效益风险比大多不利应谨慎;度普利尤单抗为选项之一但需注意眼副作用和费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and pathogenic variabilities, the patient's age and also target flare prevention. Basic therapy includes hydrating and barrier-stabilizing topical treatment universally applied, as well as avoiding specific and unspecific provocation factors. Visible skin lesions are treated with anti-inflammatory topical agents such as corticosteroids and calcineurin inhibitors (tacrolimus and pimecrolimus), which are preferred in sensitive locations. Topical tacrolimus and some mid-potency corticosteroids are proven agents for proactive therapy, which is defined as the long-term intermittent anti-inflammatory therapy of frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is a rapidly changing field requiring monitoring. Oral corticosteroids have a largely unfavourable benefit-risk ratio. The IL-4R-blocker dupilumab is a safe, effective and licensed, but expensive, treatment option with potential ocular side-effects. Other biologicals targeting key pathways in the atopic immune response, as well as different Janus kinase inhibitors, are among emerging treatment options. Dysbalanced microbial colonization and infection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) only have limited effects on AD-related itch and eczema lesions. Adjuvant therapy includes UV irradiation, preferably narrowband UVB or UVA1. Coal tar may be useful for atopic hand and foot eczema. Dietary recommendations should be patient-specific, and elimination diets should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. Efficacy-proven 'Eczema school' educational programmes and therapeutic patient education are recommended for both children and adults.
引用
- Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020. PMID: 33205485. doi:10.1111/jdv.16892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。